Two Sigma Advisers
VRTX icon

Two Sigma Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Two Sigma Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3,000
Closed -$356K – 2409
2014
Q4 		$356K Buy
+3,000
New +$338K ﹤0.01% 1842

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Two Sigma Advisers's VRTX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 98,360 shares — an estimated $44.6M sold.

Two Sigma Advisers first reported a position in VRTX in Q2 2015 and held it in 41 quarters. The position peaked at $353M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 98,360 Vertex Pharmaceuticals shares in Q1 2026, an estimated $44.6M.
  • Two Sigma Advisers first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 41 quarters.
  • Two Sigma Advisers's Vertex Pharmaceuticals position peaked at $353M in Q2 2020.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.